| Dr Charles Calvin Brown, MD | |
|
1403 Greenbrier Pkwy, Ste 401, Chesapeake, VA 23320-0407 | |
| (757) 965-4018 | |
| (757) 965-4268 |
| Full Name | Dr Charles Calvin Brown |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 40 Years |
| Location | 1403 Greenbrier Pkwy, Chesapeake, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740283191 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 0101234662 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Barnabas Hospital | Bronx, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bronx Anesthesia Services, Pc | 9739360421 | 16 |
News Archive
Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. The study is published in Blood Cancer Journal by co-senior authors Drs. David Conrad and John Bell of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa).
Golub Capital today announced that it has provided $12.0 million of senior subordinated debt to support the recapitalization and ongoing growth of Integrated DNA Technologies, Inc. This transaction marks the first investment made by GC 2009 Mezzanine Partners, L.P., which is Golub Capital's sixth fund dedicated to middle market mezzanine debt financings.
Results of recent clinical trials carried out on type 1 diabetics by Nemaura Pharma using its Memspatch Insulin Micro-needle Device (IMD) will come as a relief to those who fear needles and injections, a condition medically known as trypanophobia, affecting 10 percent of the world's population.
Northeast Ohio Medical University researcher and professor of anatomy and neurobiology Jianxin Bao, Ph.D., has received a large federal grant to produce the first human treatment for tinnitus, a disruptive hearing impairment marked by the perception of ringing or buzzing in one or both ears.
› Verified 1 days ago
| Entity Name | Bronx Anesthesia Services, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225330103 PECOS PAC ID: 9739360421 Enrollment ID: O20110301000635 |
News Archive
Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. The study is published in Blood Cancer Journal by co-senior authors Drs. David Conrad and John Bell of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa).
Golub Capital today announced that it has provided $12.0 million of senior subordinated debt to support the recapitalization and ongoing growth of Integrated DNA Technologies, Inc. This transaction marks the first investment made by GC 2009 Mezzanine Partners, L.P., which is Golub Capital's sixth fund dedicated to middle market mezzanine debt financings.
Results of recent clinical trials carried out on type 1 diabetics by Nemaura Pharma using its Memspatch Insulin Micro-needle Device (IMD) will come as a relief to those who fear needles and injections, a condition medically known as trypanophobia, affecting 10 percent of the world's population.
Northeast Ohio Medical University researcher and professor of anatomy and neurobiology Jianxin Bao, Ph.D., has received a large federal grant to produce the first human treatment for tinnitus, a disruptive hearing impairment marked by the perception of ringing or buzzing in one or both ears.
› Verified 1 days ago
| Entity Name | Sbh Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740595917 PECOS PAC ID: 3072798941 Enrollment ID: O20110420000217 |
News Archive
Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. The study is published in Blood Cancer Journal by co-senior authors Drs. David Conrad and John Bell of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa).
Golub Capital today announced that it has provided $12.0 million of senior subordinated debt to support the recapitalization and ongoing growth of Integrated DNA Technologies, Inc. This transaction marks the first investment made by GC 2009 Mezzanine Partners, L.P., which is Golub Capital's sixth fund dedicated to middle market mezzanine debt financings.
Results of recent clinical trials carried out on type 1 diabetics by Nemaura Pharma using its Memspatch Insulin Micro-needle Device (IMD) will come as a relief to those who fear needles and injections, a condition medically known as trypanophobia, affecting 10 percent of the world's population.
Northeast Ohio Medical University researcher and professor of anatomy and neurobiology Jianxin Bao, Ph.D., has received a large federal grant to produce the first human treatment for tinnitus, a disruptive hearing impairment marked by the perception of ringing or buzzing in one or both ears.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles Calvin Brown, MD 411 Inlet Dr, Elizabeth City, NC 27909-3231 Ph: (252) 338-3858 | Dr Charles Calvin Brown, MD 1403 Greenbrier Pkwy, Ste 401, Chesapeake, VA 23320-0407 Ph: (757) 965-4018 |
News Archive
Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. The study is published in Blood Cancer Journal by co-senior authors Drs. David Conrad and John Bell of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa).
Golub Capital today announced that it has provided $12.0 million of senior subordinated debt to support the recapitalization and ongoing growth of Integrated DNA Technologies, Inc. This transaction marks the first investment made by GC 2009 Mezzanine Partners, L.P., which is Golub Capital's sixth fund dedicated to middle market mezzanine debt financings.
Results of recent clinical trials carried out on type 1 diabetics by Nemaura Pharma using its Memspatch Insulin Micro-needle Device (IMD) will come as a relief to those who fear needles and injections, a condition medically known as trypanophobia, affecting 10 percent of the world's population.
Northeast Ohio Medical University researcher and professor of anatomy and neurobiology Jianxin Bao, Ph.D., has received a large federal grant to produce the first human treatment for tinnitus, a disruptive hearing impairment marked by the perception of ringing or buzzing in one or both ears.
› Verified 1 days ago